Loading...
•
Dec 31, 2020
Vanda Q4 2020 Earnings Report
Reported an 11% increase in total revenues compared to Q4 2019.
Key Takeaways
Vanda Pharmaceuticals reported Q4 2020 total revenues of $67.7 million, an 11% increase compared to Q4 2019. Income before taxes was $10.9 million in the fourth quarter of 2020 compared to $5.8 million in the fourth quarter of 2019.
Total net product sales from HETLIOZ® and Fanapt® were $67.7 million in Q4 2020, an 11% increase compared to Q4 2019.
HETLIOZ® net product sales were $44.2 million in Q4 2020, a 14% increase compared to Q4 2019.
Fanapt® net product sales were $23.5 million in Q4 2020, a 5% increase compared to Q4 2019.
Income before taxes was $10.9 million in Q4 2020 compared to $5.8 million in Q4 2019.
Revenue by Segment
Forward Guidance
Vanda expects full year 2021 total revenues to be between $270 million and $300 million. Year-end 2021 Cash expected to be greater than $400 million.
Positive Outlook
- Full Year 2021 Total revenues expected to be between $270 to $300 million
- HETLIOZ® net product sales expected to be between $180 to $200 million
- Fanapt® net product sales expected to be between $90 to $100 million
- Year-end 2021 Cash expected to be greater than $400 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...